GSK’s Stiefel Adds Psoriasis/Atopical Dermatitis Candidate In Licensing Deal
This article was originally published in The Pink Sheet Daily
For about $34 million, Stiefel gets development and commercialization rights in most of the world to a novel, non-steroidal, topical anti-inflammatory compound in Phase II.
You may also be interested in...
Activist investor Carl Icahn is at it again, announcing plans May 30 to propose a minority slate of new board members for patent-cliff-challenged specialty pharma Forest Laboratories.
Acquisition more than doubles GSK’s dermatology sales to $1.5 billion, creating a global specialist business across prescription and OTC drugs.
Completion of the $640 million acquisition combines Stiefel’s dermatology portfolio with Connectics’ patented drug delivery technology.